Linagliptin Tablets

Therapeutic Indication

Type 2 Diabetes Mellitus

Blood sugar control in adults

Used as monotherapy or with other antidiabetic agents

+91 85919 78885

Linagliptin

Tablet

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that helps manage type 2 diabetes by increasing incretin activity. It enhances insulin secretion and reduces glucagon release, leading to improved blood sugar control.

Speciality	Endocrinology \| Internal Medicine
Tags	Diabetes Care \| Blood Sugar Control
Strength	5 mg
Packing Size	10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Linagliptin inhibits the DPP-4 enzyme, preventing the breakdown of incretin hormones. This increases insulin secretion in response to meals and decreases glucagon levels, resulting in lower blood glucose.

Pharmacokinetics

Absorption: Rapid oral absorption
Distribution: Protein-bound
Metabolism: Minimal hepatic metabolism
Elimination: Primarily via bile and feces
Half-life: ~12 hrs

Side Effects

Nasopharyngitis
Cough
Joint pain
Hypoglycemia (when combined with other agents)
Pancreatitis (rare)

Contraindication

Type 1 Diabetes
Diabetic ketoacidosis
Pregnancy and breastfeeding
Children under 18 years

Interaction

Other antidiabetic drugs (risk of hypoglycemia)
Rifampicin (reduced efficacy)
Insulin and sulfonylureas (enhanced hypoglycemia risk)

Warning and Precautions

Monitor blood sugar regularly
Watch for signs of pancreatitis
Use with caution in elderly patients
Not recommended in severe hepatic impairment

Dosage

As directed by the Physician.

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.